Antithrombotic potential of olive oil administration in rabbits with elevated cholesterol.
Olive oil is the main source of dietary fatty acids in the Mediterranean region. The objective of this study was to evaluate the effect of dietary supplementation with virgin olive oil in an experimental model with rabbits fed an atherogenic diet (saturated fat 48% of total fat). Four different groups of 10 animals each were studied: (1) normolipemic diet (NLD), (2) atherogenic diet or saturated fatty acid-enriched diet (SFAED), (3) NLD with 15% olive oil (NLD+OLIV), and (4) SFAED with 15% virgin olive oil (SFAED+OLIV). The animals were fed the experimental diets for 6 weeks, after which we determined serum lipid profile (total cholesterol, HDL-cholesterol, and triglycerides), platelet aggregation, platelet thromboxane B(2), aortic prostacyclin, and platelet and vascular lipid peroxidation. Scanning electron microscopic images of the vascular endothelium were studied, as were morphometric parameters in the arterial wall and thrombogenicity of the subendothelium (annular perfusion chamber). Animals fed the SFAED showed platelet hyperactivity and increased subendothelial thrombogenicity. Animals fed the SFAED+OLIV showed, compared with the SFAED group, an improved lipid profile with decreased platelet hyperactivity and subendothelial thrombogenicity and less severe morphological lesions of the endothelium and vascular wall. We conclude that supplementation of the SFAED with 15% olive oil reduced vascular thrombogenicity and platelet activation in rabbits. Although the percentage of olive oil in the diet was higher than the amount in the human diet, these results may be helpful in determining the effect of olive oil in the human thrombogenic system.
De La Cruz
J P
JP
Department of Pharmacology and Therapeutics, School of Medicine, University of Málaga, Spain. jpcruz@uma.es
Villalobos
M A
MA
Carmona
J A
JA
Martín-Romero
M
M
Smith-Agreda
J M
JM
de la Cuesta
F S
FS
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000818:Animals; D001011:Aorta; D001161:Arteriosclerosis / Q000178:diet therapy; D002784:Cholesterol / Q000097:blood*; D004036:Diet, Atherogenic; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D004730:Endothelium, Vascular / Q000737:chemistry / Q000166:cytology / Q000187:drug effects; D005227:Fatty Acids / Q000008:administration & dosage / Q000494:pharmacology; D005231:Fatty Acids, Unsaturated / Q000008:administration & dosage / Q000494:pharmacology; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D006949:Hyperlipidemias / Q000178:diet therapy; D008055:Lipids / Q000032:analysis / Q000097:blood; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D008855:Microscopy, Electron, Scanning; D000069463:Olive Oil; D010938:Plant Oils / Q000008:administration & dosage / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects; D011817:Rabbits; D013314:Stress, Mechanical; D013927:Thrombosis / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D013929:Thromboxane B2 / Q000097:blood
D005227:Fatty Acids; D005231:Fatty Acids, Unsaturated; D005343:Fibrinolytic Agents; D008055:Lipids; D000069463:Olive Oil; D010938:Plant Oils; D008315:Malondialdehyde; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D002784:Cholesterol